DE69431993D1 - In situ modifikation und manipulation von stammzellen des zentralen nervensystems - Google Patents
In situ modifikation und manipulation von stammzellen des zentralen nervensystemsInfo
- Publication number
- DE69431993D1 DE69431993D1 DE69431993T DE69431993T DE69431993D1 DE 69431993 D1 DE69431993 D1 DE 69431993D1 DE 69431993 T DE69431993 T DE 69431993T DE 69431993 T DE69431993 T DE 69431993T DE 69431993 D1 DE69431993 D1 DE 69431993D1
- Authority
- DE
- Germany
- Prior art keywords
- cells
- situ
- stem cells
- manipulation
- nervous system
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 210000000130 stem cell Anatomy 0.000 title abstract 2
- 210000003169 central nervous system Anatomy 0.000 title 1
- 230000004048 modification Effects 0.000 title 1
- 238000012986 modification Methods 0.000 title 1
- 210000004027 cell Anatomy 0.000 abstract 6
- 238000011065 in-situ storage Methods 0.000 abstract 3
- 239000002243 precursor Substances 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000003102 growth factor Substances 0.000 abstract 2
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1761—Apoptosis related proteins, e.g. Apoptotic protease-activating factor-1 (APAF-1), Bax, Bax-inhibitory protein(s)(BI; bax-I), Myeloid cell leukemia associated protein (MCL-1), Inhibitor of apoptosis [IAP] or Bcl-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0065—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2468—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)
- C12N9/2471—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01023—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14950893A | 1993-11-09 | 1993-11-09 | |
PCT/CA1994/000614 WO1995013364A1 (en) | 1993-11-09 | 1994-11-08 | In situ modification and manipulation of stem cells of the central nervous system |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69431993D1 true DE69431993D1 (de) | 2003-02-13 |
DE69431993T2 DE69431993T2 (de) | 2003-11-27 |
Family
ID=22530608
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69431993T Expired - Lifetime DE69431993T2 (de) | 1993-11-09 | 1994-11-08 | In situ modifikation und manipulation von stammzellen des zentralen nervensystems |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP0728194B1 (de) |
JP (1) | JP3952508B2 (de) |
CN (1) | CN1141058A (de) |
AT (1) | ATE230795T1 (de) |
AU (1) | AU697894B2 (de) |
CA (1) | CA2175992C (de) |
DE (1) | DE69431993T2 (de) |
DK (1) | DK0728194T3 (de) |
ES (1) | ES2189807T3 (de) |
FI (1) | FI120455B (de) |
NO (1) | NO317724B1 (de) |
WO (1) | WO1995013364A1 (de) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1170435A (zh) * | 1994-11-14 | 1998-01-14 | 纽罗斯菲里斯控股有限公司 | 神经干细胞增殖的调节 |
AU2019997A (en) * | 1996-03-26 | 1997-10-17 | Neurospheres Holdings Ltd | Manipulation of mitotically active cells of the hippocampal region of the brain |
US7544511B2 (en) | 1996-09-25 | 2009-06-09 | Neuralstem Biopharmaceuticals Ltd. | Stable neural stem cell line methods |
US6787355B1 (en) | 1996-08-26 | 2004-09-07 | Mcgill University | Multipotent neural stem cells from peripheral tissues and uses thereof |
US6969608B1 (en) | 1996-08-26 | 2005-11-29 | Mcgill University | Pharmaceuticals containing multipotential precursor cells from tissues containing sensory receptors |
CA2216439A1 (en) * | 1996-09-25 | 1998-03-25 | Derek Van Der Kooy | Pharmaceuticals containing retinal stem cells |
CA2266659A1 (en) * | 1996-11-15 | 1998-05-28 | Paule Poulin | Pretreatment with growth factors to protect against cns damage |
US20020123143A1 (en) | 1997-08-22 | 2002-09-05 | Jean Toma | Multipotent stem cells from peripheral tissues and uses thereof |
US6093531A (en) | 1997-09-29 | 2000-07-25 | Neurospheres Holdings Ltd. | Generation of hematopoietic cells from multipotent neural stem cells |
US6165783A (en) * | 1997-10-24 | 2000-12-26 | Neuro Spheres Holdings Ltd. | Erythropoietin-mediated neurogenesis |
US6541247B1 (en) | 1998-06-25 | 2003-04-01 | Neuronova Ab | Method of isolating ependymal neural stem cells |
SE9802264D0 (sv) * | 1998-06-25 | 1998-06-25 | Neuronova Ab | A method of isolating cells |
US7544509B2 (en) | 2000-01-24 | 2009-06-09 | Mcgill University | Method for preparing stem cell preparations |
JP2003521910A (ja) | 2000-02-11 | 2003-07-22 | ザ スキーペンズ アイ リサーチ インスティテュート インコーポレイテッド | 網膜幹細胞の分離及び移植 |
WO2002069975A1 (en) * | 2001-03-02 | 2002-09-12 | Stem Cell Therapeutics Inc. | Use of estrogen to induce neural stem cell increase |
JP3993560B2 (ja) | 2001-08-30 | 2007-10-17 | ステム セル セラピューティクス インコーポレイテッド | 神経幹細胞の分化およびその治療用途 |
EP1430114B1 (de) | 2001-09-14 | 2012-01-18 | Stem Cell Therapeutics Inc. | Prolaktin-induzierte zunahme an neuronalen stammzellen und dessen therapeutische anwendung |
US7687505B2 (en) * | 2002-01-14 | 2010-03-30 | Board Of Trustees Of The University Of Illinois | Use of modified pyrimidine compounds to promote stem cell migration and proliferation |
CA2492542A1 (en) * | 2002-07-30 | 2004-02-05 | Stem Cell Therapeutics Inc. | Oligodendrocyte production from multipotent neural stem cells |
US20040185429A1 (en) | 2002-12-09 | 2004-09-23 | Judith Kelleher-Andersson | Method for discovering neurogenic agents |
US8293488B2 (en) | 2002-12-09 | 2012-10-23 | Neuralstem, Inc. | Method for screening neurogenic agents |
US8093205B2 (en) | 2003-12-01 | 2012-01-10 | Medtronic, Inc. | Method for treating a stroke by implanting a first therapy delivery element in the CNS and a second therapy delivery element in a damaged tissue of the CNS to promote neurogenesis |
CA2556266A1 (en) | 2004-02-13 | 2005-08-25 | Stem Cell Therapeutics Corp. | Use of luteinizing hormone (lh), and chorionic gonadotropin (hcg) for proliferation of neural stem cells and neurogenesis |
EP2913393B8 (de) | 2004-11-17 | 2020-02-26 | Seneca Biopharma, Inc. | Transplantation menschlicher Nervenzellen zur Behandlung neurodegenerativer Erkrankungen |
AU2006297041A1 (en) | 2005-09-27 | 2007-04-05 | Stem Cell Therapeutics Corp. | Oligodendrocyte precursor cell proliferation regulated by prolactin |
WO2007106986A1 (en) | 2006-03-17 | 2007-09-27 | Stem Cell Therapeutics Corp. | Dosing regimes for lh or hcg and epo for treatment of neurological disorders |
WO2008093827A1 (ja) * | 2007-02-01 | 2008-08-07 | Osaka Industrial Promotion Organization | 中枢神経障害治療剤及び中枢神経障害の治療方法 |
JP2009278873A (ja) * | 2008-05-19 | 2009-12-03 | Japan Health Science Foundation | 培地および培養方法 |
US9540611B2 (en) | 2010-07-28 | 2017-01-10 | Neuralstem, Inc. | Methods for treating and/or reversing neurodegenerative diseases and/or disorders |
US10758572B2 (en) | 2012-02-17 | 2020-09-01 | The Schepens Eye Research Institute | Phenotype profile of human retinal progenitor cells |
WO2014157047A1 (ja) * | 2013-03-27 | 2014-10-02 | 千葉県 | 神経変性疾患治療剤 |
WO2016064737A1 (en) | 2014-10-20 | 2016-04-28 | Neuralstem, Inc. | Stable neural stem cells comprising an exogenous polynucleotide coding for a growth factor and methods of use thereof |
CN113564123A (zh) | 2014-10-24 | 2021-10-29 | 大日本住友制药株式会社 | 神经组织的制备方法 |
SG11201809201UA (en) * | 2016-04-22 | 2018-11-29 | Sumitomo Dainippon Pharma Co Ltd | Method for producing retinal tissue |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ226171A (en) * | 1987-09-18 | 1990-06-26 | Ethicon Inc | Gel formulation containing polypeptide growth factor |
US5034375A (en) * | 1988-08-10 | 1991-07-23 | Institute Of Molecular Biology, Inc. | Process of wound healing using PDGF and EGF |
US5082670A (en) * | 1988-12-15 | 1992-01-21 | The Regents Of The University Of California | Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system |
IT1240683B (it) * | 1990-04-26 | 1993-12-17 | Zambon Spa | Composizione farmaceutica contenente egf |
JPH04224522A (ja) * | 1990-04-27 | 1992-08-13 | Merck & Co Inc | 繊維芽細胞増殖因子含有組成物による禿頭症の治療又は予防方法 |
AU3062392A (en) * | 1991-11-04 | 1993-06-07 | Novo Nordisk A/S | Pdgf gel formulation |
ATE262912T1 (de) * | 1993-01-29 | 2004-04-15 | Neurospheres Holdings Ltd | Genetische modifikation von neuralen stammzellen |
-
1994
- 1994-11-08 AT AT94931482T patent/ATE230795T1/de active
- 1994-11-08 AU AU80561/94A patent/AU697894B2/en not_active Ceased
- 1994-11-08 DE DE69431993T patent/DE69431993T2/de not_active Expired - Lifetime
- 1994-11-08 JP JP51349995A patent/JP3952508B2/ja not_active Expired - Fee Related
- 1994-11-08 DK DK94931482T patent/DK0728194T3/da active
- 1994-11-08 EP EP94931482A patent/EP0728194B1/de not_active Expired - Lifetime
- 1994-11-08 ES ES94931482T patent/ES2189807T3/es not_active Expired - Lifetime
- 1994-11-08 CA CA002175992A patent/CA2175992C/en not_active Expired - Fee Related
- 1994-11-08 CN CN94194785A patent/CN1141058A/zh active Pending
- 1994-11-08 WO PCT/CA1994/000614 patent/WO1995013364A1/en active IP Right Grant
-
1996
- 1996-04-30 FI FI961855A patent/FI120455B/fi not_active IP Right Cessation
- 1996-05-08 NO NO19961859A patent/NO317724B1/no not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
FI961855A0 (fi) | 1996-04-30 |
FI961855A (fi) | 1996-06-04 |
EP0728194A1 (de) | 1996-08-28 |
ES2189807T3 (es) | 2003-07-16 |
DK0728194T3 (da) | 2003-04-22 |
DE69431993T2 (de) | 2003-11-27 |
WO1995013364A1 (en) | 1995-05-18 |
NO317724B1 (no) | 2004-12-13 |
CA2175992C (en) | 2008-04-01 |
CA2175992A1 (en) | 1995-05-18 |
NO961859D0 (no) | 1996-05-08 |
EP0728194B1 (de) | 2003-01-08 |
ATE230795T1 (de) | 2003-01-15 |
CN1141058A (zh) | 1997-01-22 |
FI120455B (fi) | 2009-10-30 |
AU8056194A (en) | 1995-05-29 |
AU697894B2 (en) | 1998-10-22 |
JPH09507747A (ja) | 1997-08-12 |
JP3952508B2 (ja) | 2007-08-01 |
NO961859L (no) | 1996-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69431993D1 (de) | In situ modifikation und manipulation von stammzellen des zentralen nervensystems | |
IL147990A0 (en) | Multipotent adult stem cells and methods for isolation | |
DE69535328D1 (de) | In-vitro wachstum von langerhans'schen inseln und ihre verwendungen | |
ATE286126T1 (de) | Glialmitogene faktoren, ihre herstellung und verwendung | |
GB9308271D0 (en) | Method of isolating and/or enriching and/or selectively propagating pluripotential animal cells and animals for use in said method | |
GEP20063830B (en) | Nogo Receptor-Mediated Blockade of Axonal Growth | |
DE69435038D1 (de) | Aktivin rezeptor-ähnliche kinase (alk), gehörend zur tgf rezeptorfamilie und/oder zur bmp rezeptorfamilie | |
AU2821601A (en) | Multipotent neural stem cells from peripheral tissues and uses thereof | |
DE3779149D1 (de) | Galanthamin oder dessen analoge zur behandlung der alzheimerschen krankheit. | |
ATE328067T1 (de) | Isolierung von mesenchymalen stammzellen und deren verwendung | |
ES2008974A6 (es) | Formulacion liquida de enzimas para aplicacion tecnica, utilizaciones y procedimientos de empleo para desencalado, adobo, remojo y desengrasado de pieles en tripa. | |
DE60122767D1 (de) | Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns | |
DK0892849T3 (da) | Fremgangsmåde til anvendelse af obese-genet og dets genprodukt til stimulering af hæmatopoietisk udvikling | |
WO2000066730A3 (en) | Laminin 2 and methods for its use | |
ATE345496T1 (de) | In-vitro-musters für zns - funktion und dysfunktion | |
ATE473273T1 (de) | Angereicherte zellpopulationen des zentralen nervensystems | |
FI854843A0 (fi) | Foerfarande foer producering av ligninolytiskt ensym med hjaelp av kultur av mikro-organismer av stammen phanerochaete chrysosporium. | |
MY132553A (en) | Methods of making hiv-protease inhibitors and intermediates for making hiv-protease inhibitors | |
EP0244361A3 (en) | Individual beta-form crystals of tetrakis-û3-(3,5-di-t-butyl-4-hydroxyphenyl)-propionyloxymethyl¨ methane and process for their manufacture | |
Pintér et al. | Calpeptin, a calpain inhibitor, promotes neurite elongation in differentiating PC12 cells | |
GB1292701A (en) | Improvements in or relating to the thermal hydrodealkylation of alkylbenzene compounds | |
IS5613A (is) | Notkun CD137 til að stuðla að fjölgun jaðar-einkjörnunga | |
DE69908288D1 (de) | Verfahren zur Herstellung von UCN-01 | |
MY105082A (en) | Separation process | |
ATE22010T1 (de) | Antipsychotische trans-dihydrolisuride. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |